Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

45 citing papers in PubMed.

1. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.Alzheimer's research & therapy · 2020
   Trial
2. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.Alzheimer's research & therapy · 2019
   Trial
3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.Journal of Alzheimer's disease : JAD · 2019
   Trial
4. Amyloid Alpha: The Neglected Cousin of Amyloid Beta.Chembiochem : a European journal of chemical biology · 2026
   Review
5. Population and single-cell analyses reveal immune cell-specific expression profiles associated with Alzheimer's disease risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
   Article
6. Rescuing Verubecestat: An Integrative Molecular Modeling and Simulation Approach for Designing Next-Generation BACE1 Inhibitors.International journal of molecular sciences · 2025
   Article
7. NeuroMusic: protocol for a randomised-controlled trial of keyboard and singing music training programmes for older adults with mild cognitive impairment.BMJ open · 2025
   Article
8. Targeting cholinergic dysfunction in Alzheimer's disease: Development of next-generation galantamine derivatives.Journal, genetic engineering & biotechnology · 2025
   Article
9. Population-Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study.Clinical pharmacology and therapeutics · 2025
   Article
10. Plasma proteomics for cognitive decline and dementia-A Southeast Asian cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
11. Impact of hypertension prevalence trend on mortality and burdens of dementia and disability in England and Wales to 2060: a simulation modelling study.The lancet. Healthy longevity · 2023
    Article
12. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.The FEBS journal · 2023
    Review
13. Galantamine Based Novel Acetylcholinesterase Enzyme Inhibitors: A Molecular Modeling Design Approach.Molecules (Basel, Switzerland) · 2023
    Article
14. Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges.Aging and disease · 2022
    Article
15. Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases.Nature aging · 2022
    Article
16. Interactions between cigarette smoking and cognitive status on functional connectivity of the cortico-striatal circuits in individuals without dementia: A resting-state functional MRI study.CNS neuroscience & therapeutics · 2022
    Article
17. The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by α-secretase ADAM10.The Journal of biological chemistry · 2022
    Article
18. AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer's disease model.EMBO molecular medicine · 2022
    Article
19. Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
20. β-secretase inhibition prevents structural spine plasticity deficits inFrontiers in aging neuroscience · 2022
    Article

Corrections and comments

• Comment on
  Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as